- Home
- RNAC vs EOD Comparison
RNAC vs EOD Comparison
Compare RNAC & EOD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- RNAC
- EOD
- Stock Information
- Founded
- RNAC 2007
- EOD 2007
- Country
- RNAC United States
- EOD United States
- Employees
- RNAC N/A
- EOD N/A
- Industry
- RNAC Biotechnology: Pharmaceutical Preparations
- EOD Investment Managers
- Sector
- RNAC Health Care
- EOD Finance
- Exchange
- RNAC Nasdaq
- EOD Nasdaq
- Market Cap
- RNAC 276.3M
- EOD 245.0M
- IPO Year
- RNAC 2016
- EOD N/A
- Fundamental
- Price
- RNAC $9.67
- EOD $5.75
- Analyst Decision
- RNAC Strong Buy
- EOD
- Analyst Count
- RNAC 4
- EOD 0
- Target Price
- RNAC $40.00
- EOD N/A
- AVG Volume (30 Days)
- RNAC 83.4K
- EOD 118.1K
- Earning Date
- RNAC 11-06-2025
- EOD 01-01-0001
- Dividend Yield
- RNAC N/A
- EOD 9.28%
- EPS Growth
- RNAC N/A
- EOD N/A
- EPS
- RNAC N/A
- EOD N/A
- Revenue
- RNAC $1,026,000.00
- EOD N/A
- Revenue This Year
- RNAC N/A
- EOD N/A
- Revenue Next Year
- RNAC N/A
- EOD N/A
- P/E Ratio
- RNAC N/A
- EOD N/A
- Revenue Growth
- RNAC N/A
- EOD N/A
- 52 Week Low
- RNAC $8.46
- EOD $3.73
- 52 Week High
- RNAC $26.50
- EOD $4.71
- Technical
- Relative Strength Index (RSI)
- RNAC 44.74
- EOD 59.91
- Support Level
- RNAC $9.87
- EOD $5.56
- Resistance Level
- RNAC $10.48
- EOD $5.77
- Average True Range (ATR)
- RNAC 0.62
- EOD 0.06
- MACD
- RNAC 0.07
- EOD 0.01
- Stochastic Oscillator
- RNAC 41.25
- EOD 82.68
About RNAC Cartesian Therapeutics Inc.
Cartesian Therapeutics Inc is a clinical-stage biopharmaceutical company. The company uses its ImmTOR immune tolerance platform, which is designed to give rise to antigen-specific immunity, mitigating unwanted immune responses. The company leverages its proprietary technology and manufacturing platform to introduce one or more mRNA molecules into cells to enhance their function.
About EOD Allspring Global Dividend Opportunity Fund of Beneficial Interest
Allspring Global Dividend Opportunity Fund is a diversified closed-end management investment company. Its primary investment objective is to seek a high level of current income. The fund's secondary objective is the long-term growth of capital. The fund allocates its assets between two separate investment strategies or sleeves. Under normal market conditions, the fund allocates approximately 80% of its total assets to an equity sleeve comprised of common stocks.